13 Best Multibagger Stocks to Invest in Now
The global economic and geopolitical environment in 2025 is marked by uncertainty, trade tensions, and shifting monetary policies.
Lexicon Pharmaceuticals Inc. (LXRX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Siren L.L.C. Raymond Debbane | 38,918,903 | $17,933,831 | 1.01% | |
| 2. | Schonfeld Strategic Advisors Ryan Tolkin (Cio) | 8,212,993 | $3,784,546 | +9% | 0.02% |
| 3. | Ikarian Capital Neil Shahrestani | 1,417,952 | $653,393 | -9% | 0.08% |
| 4. | AQR Capital Management Cliff Asness | 1,173,225 | $540,622 | 0% | |
| 5. | Tang Capital Management Kevin C. Tang | 1,150,268 | $530,043 | +36% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.05 | 90,000 | Officer, Director | 914,359 | 2023-11-16 | Filing | |
| $1.01 | 10,000 | Officer, Director | 824,359 | 2023-11-10 | Filing | |
| $1.03 | 148,820 | Director | 1,340,847 | 2023-10-12 | Filing | |
| $1.08 | 342,874 | Director | 1,192,027 | 2023-10-11 | Filing | |
| $1.14 | 508,306 | Director | 849,153 | 2023-10-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.93 | 12,000 | Officer | 71,766 | 2021-03-15 | Filing | |
| $6.90 | 10,912 | Officer | 71,766 | 2021-03-15 | Filing | |
| $12.91 | 10,000 | Officer | 25,643 | 2018-06-08 | Filing | |
| $15.00 | 1,500 | Officer | 15,946 | 2016-06-06 | Filing | |
| $13.00 | 6,000 | Officer | 15,946 | 2016-05-23 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 136,180,481 | $62,643,021 | 7.08% | |
| 2. | 34,543,197 | $15,917,505 | 0% | |
| 3. | 10,013,007 | $4,613,995 | 0% | |
| 4. | 9,557,175 | $4,405,858 | 0% | |
| 5. | 3,689,271 | $1,700,415 | 0% |
News See All
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Call Transcript
Operator: Welcome to the Lexicon Pharmaceuticals First Quarter 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2024 Earnings Call Transcript
Operator: Welcome to the Lexicon Pharmaceuticals Fourth Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
10 Best Diabetes Stocks To Buy Under $10
About 422 million people worldwide have diabetes, according to the WHO, and most of them live in low- or middle-income nations. Every year, diabetes directly causes 1.5 million deaths on average.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Lexicon Pharmaceuticals Third Quarter 2024 Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions].
10 Best Multibagger Penny Stocks of 2025
The term "multibagger" was coined by Peter Lynch in his book titled "One Up On Wall Street" to describe those stocks whose share prices increase several times more than an investor's original investment...
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q2 2024 Earnings Call Transcript
Operator: Good day and welcome to Lexicon Pharmaceuticals Second Quarter 2024 Financial Results Conference Call. All participants will be in a listen-only mode.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2024 Earnings Call Transcript
Operator: Good day, everyone, and welcome to the Lexicon Pharmaceuticals First Quarter 2024 Financial Results Conference Call. At this time all participants are in a listen-only mode.
15 Hot Penny Stocks On the Move
Strong inflation data from January and the Fed's indications that it would take its time before initiating rate cuts threw cold water on investors' hopes of getting rid of uncertainties.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2023 Earnings Call Transcript
Operator: Good day and welcome to the Lexicon Pharmaceuticals' Third Quarter 2023 Financial Results Conference Call. Today all participants will be in a listen-only mode.
Billionaire Hedge Funds
